Incyte Corp logo

Incyte Corp

NAS:INCY (USA)  
10
$ 58.79 -1.56 (-2.58%) 11:09 PM EST
On watch
P/E:
36.31
P/B:
2.79
Market Cap:
$ 13.17B
Enterprise V:
$ 10.14B
Volume:
1.81M
Avg Vol (2M):
1.61M
Warning! GuruFocus detected 1 Severe warning sign with INCY. Try a 7-Day Free Trial to check it out.
Also Trade In:
Volume:
1.81M
Market Cap $:
13.17B
PE Ratio:
36.31
Avg Vol (2M):
1.61M
Enterprise Value $:
10.14B
PB Ratio:
2.79
Alerts Website SEC Filings Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

Business Description

Incyte Corp logo
Incyte Corp
NAICS : 541714 SIC : 8731
ISIN : US45337C1027
https://www.incyte.com
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Compare
Compare
RPRXLEGNTECHSRPTBMRNUTHRJAZZROIVBGNEEXELOCSE:NOVO BVRTXREGNASX:CSLMRNAXKRX:207940SGENXBRU:ARGXBNTXHKSE:02269
Traded in other countries / regions
INCY.USAI1NC34.BrazilICY.GermanyINCY.Austria0J9P.UKINCY.Mexico
IPO Date
1993-11-03
Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financial Strength

10/10
Name Current Vs Industry Vs History
Cash-To-Debt 86.14
Equity-to-Asset 0.76
Debt-to-Equity 0.01
Debt-to-EBITDA 0.06
Interest Coverage 182.59
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.85
Distress
Grey
Safe
Beneish M-Score -2.91
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

6/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 15.2
3-Year EBITDA Growth Rate 2.4
3-Year EPS without NRI Growth Rate -9.5
3-Year FCF Growth Rate 11.1
3-Year Book Growth Rate 17.7
Future 3-5Y EPS without NRI Growth Rate 29.9
Future 3-5Y Total Revenue Growth Rate 10.88

Momentum Rank

4/10
Name Current Vs Industry Vs History
5-Day RSI 20.11
9-Day RSI 25.06
14-Day RSI 29.95
6-1 Month Momentum % -11.72
12-1 Month Momentum % -2.92

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.81
Quick Ratio 3.78
Cash Ratio 3.06
Days Inventory 66.97
Days Sales Outstanding 66.65
Days Payable 258.71

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1
Shareholder Yield % 0.02

Profitability Rank

7/10
Name Current Vs Industry Vs History
Gross Margin % 93.2
Operating Margin % 12.64
Net Margin % 10.43
ROE % 8.37
ROA % 6.39
ROIC % 13.18
ROC (Joel Greenblatt) % 73.84
ROCE % 11.96
Years of Profitability over Past 10-Year 6

GF Value Rank

10/10
Name Current Vs Industry Vs History
PE Ratio 36.31
Forward PE Ratio 13.22
PE Ratio without NRI 36.31
Shiller PE Ratio 90.97
Price-to-Owner-Earnings 27.73
PS Ratio 3.79
PB Ratio 2.79
Price-to-Tangible-Book 2.95
Price-to-Free-Cash-Flow 19.07
Price-to-Operating-Cash-Flow 17.04
EV-to-EBIT 18.08
EV-to-Forward-EBIT 7.58
EV-to-EBITDA 15.96
EV-to-Forward-EBITDA 7.16
EV-to-Revenue 2.89
EV-to-Forward-Revenue 2.41
EV-to-FCF 14.54
Price-to-Projected-FCF 1.54
Price-to-Median-PS-Value 0.39
Price-to-Graham-Number 2.17
Price-to-Net-Current-Asset-Value 4.7
Price-to-Net-Cash 6.71
Earnings Yield (Greenblatt) % 5.53

Financials (Next Earnings Date:2023-11-01 Est.)

INCY's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:INCY

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Incyte Corp Executives

Details

GF Value: $89.7

INCY

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,513.286
EPS (TTM) ($) 1.63
Beta 0.56
Volatility % 27.51
14-Day RSI 29.95
14-Day ATR ($) 1.330346
20-Day SMA ($) 63.146
12-1 Month Momentum % -2.92
52-Week Range ($) 58.54 - 86.29
Shares Outstanding (Mil) 224.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Filing Date Document Date Form
No Filing Data

Incyte Corp Stock Events

Event Date Price($)
No Event Data

Incyte Corp Frequently Asked Questions

What is Incyte Corp(INCY)'s stock price today?
The current price of INCY is $58.79. The 52 week high of INCY is $86.29 and 52 week low is $58.54.
When is next earnings date of Incyte Corp(INCY)?
The next earnings date of Incyte Corp(INCY) is 2023-11-01 Est..
Does Incyte Corp(INCY) pay dividends? If so, how much?
Incyte Corp(INCY) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2023 GuruFocus.com, LLC. All Rights Reserved.